Evidence map›Paper›PMID 35504640›Full record

Trial reportBMJ open2022

Feasibility of decentralised, task-shifted hepatitis C testing and treatment services in urban Myanmar: implications for scale-up.

Bridget Louise Draper, Win Lei Yee, Sonjelle Shilton, Anna Bowring, Hla Htay, Nwe Nwe, Jessica Markby, Khin Pyone Kyi, Philippa Easterbrook, Win Naing and 5 more

Registry-linked trialOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03939013 (Hepatitis C), which is not on this map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03939013 nacompletednot on this map

Hepatitis C: Community Testing and Treatment (CT2 Study Myanmar)

TypeinterventionalSponsorMacfarlane Burnet Institute for Medical Research and Public Health LtdRan2019 to 2020Enrolled634ConditionsHepatitis CArmsXpert HCV VL
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Acceptability and Effectiveness of Point-of-Care HCV Testing in Low- and Middle-Income Countries: A Systematic Review.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Bridget Louise DraperDisease Elimination, Burnet Institute, Melbourne, Victoria, Australia bridget.draper@burnet.edu.au.ORCID 0000-0003-2624-2510
Win Lei YeeDisease Elimination, Burnet Institute Myanmar, Yangon, Myanmar.
Sonjelle ShiltonFIND, Geneva, Switzerland.ORCID 0000-0003-1569-8758
Anna BowringDisease Elimination, Burnet Institute, Melbourne, Victoria, Australia.
Hla HtayDisease Elimination, Burnet Institute Myanmar, Yangon, Myanmar.
Nwe NweFIND, Geneva, Switzerland.
Jessica MarkbyFIND, Geneva, Switzerland.
Khin Pyone KyiMyanmar Liver Foundation, Yangon, Myanmar.
Philippa EasterbrookDepartment of Global HIV, Hepatitis, and STI Programmes, World Health Organization, Geneva, Switzerland.
Win NaingMyanmar Liver Foundation, Yangon, Myanmar.
Thin Mar WinDisease Elimination, Burnet Institute Myanmar, Yangon, Myanmar.
Khin Sanda AungNational Hepatitis Control Program, Department of Public Health, Ministry of Health and Sports, Yangon, Myanmar.
Jessica HowellDisease Elimination, Burnet Institute, Melbourne, Victoria, Australia.
Alisa PedranaDisease Elimination, Burnet Institute, Melbourne, Victoria, Australia.
Margaret HellardDisease Elimination, Burnet Institute, Melbourne, Victoria, Australia.
Burnet Institute · AUFIND · CHEast Yangon General Hospital · MMMinistry of Health and Sports · MMWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

objectivesTo assess the feasibility considerations for a decentralised, one-stop-shop model of care implemented in Yangon, Myanmar.

settingTwo primary care level clinics in urban Yangon, Myanmar.

designThis is a feasibility study of a highly effective care model. Using Intervention Complexity Framework by Gericke

participantsProgrammatic data were collected from clinical records, GeneXpert device test and maintenance reports, national guidelines, product and device instructions and site monitoring visit reports. Healthcare providers involved in delivering care model contributed interview data.

resultsThe main feasibility considerations are appropriate storage for test kits and treatments (in response to temperature and humidity requirements), installation of a continuous stable electricity supply for the GeneXpert device, air-conditioning for the laboratory room hosting GeneXpert, access to a laboratory for pretreatment assessments and clear referral pathways for specialist consultation when required. Lessons from our project implementation experiences included the extensive time requirements for patient education, the importance of regular error monitoring and stock storage reviews and that flexible appointment scheduling and robust reminder system likely contributed to high retention in care.

conclusionsDetailed documentation and dissemination of feasibility requirements and implementation considerations is vital to assist others to successfully implement a similar model of care elsewhere. We provide 10 recommendations for successful implementation. TRIAL REGISTRATION NUMBER: The trial was registered at ClinicalTrials.gov NCT03939013 on May 6, 2019. This manuscript presents post-results data on feasibility.

Indexed as

HepacivirusHepatitis CFeasibility StudiesHumansMyanmarReferral and Consultationgastroenterologyhealth services administration & managementinternational health servicespublic health

Identifiers

PMID35504640
PMCPMC9066562
OpenAlexW4225391702

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.